1. First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials. (February 2017) Authors: Schuler, M.; Paz-Ares, L.; Sequist, L.V.; Tan, E.H.; Mok, T.; Hirsh, V.; O'Byrne, K.; Zhang, L.; Yamamoto, N.; Boyer, M.; Shah, R.; Bennouna, J.; Dickgreber, N.J.; De Grève, J.; Love, J.; Märten, A.; Fan, J.; Ehrnrooth, E.; Park, K.; Yang, J.C.H. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S176 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗